EGFR and neoplasm: With the approval of liquid biopsy for molecular testing of patients with NSCLC [31], typically in those cases with insufficient tumor tissue or in cases where specimens are not obtainable, and with the advent of third-generation EGFR-TKI, concerns have been raised to establish which platform would be the best to accurately evaluate EGFR mutations.